Close

Oppenheimer Upgrades Aldeyra Therapeutics (ALDX) to Outperform

April 3, 2024 7:08 AM EDT Send to a Friend
Oppenheimer analyst Justin Kim upgraded Aldeyra Therapeutics (NASDAQ: ALDX) from Perform to Outperform with a price target of $10.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login